Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2021-06-02 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
内蒙古建中律师事务所关于天士力医药集团股份有限公司2020年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and validity of the procedures, attendance, and voting results of the 2020 Annual General Meeting (AGM) of TianShiLi Pharmaceutical Group Co., Ltd. It details the convening, attendance, voting procedures, and results of the AGM, confirming compliance with relevant laws and company bylaws. The document is not the AGM materials or minutes themselves but a legal opinion on the AGM process. This fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to the official validation and announcement of the AGM voting results and procedures. The document length is short (2394 characters), and it is not a full report or presentation but a legal opinion letter tied to the AGM event.
2021-06-02 Chinese
天士力关于以集中竞价交易方式回购公司股份的回购报告书
Transaction in Own Shares Classification · 95% confidence The document is a detailed report about the company's share repurchase program, including the approval process, purpose, method, price, quantity, funding source, and impact analysis. It discusses the company's board and shareholder approvals, the timeline, and legal compliance related to the share buyback. The document is titled as a '回购报告书' which translates to 'Repurchase Report' or 'Buyback Report'. It is not a brief announcement but a comprehensive report on the share repurchase activity. This fits the definition of 'Transaction in Own Shares' (POS), which covers reports of the company buying back its own shares. The document is over 6,000 characters and contains substantive details about the repurchase, so it is not a mere announcement or regulatory filing. Therefore, the correct classification is POS with high confidence.
2021-06-02 Chinese
天士力第八届董事会第1次会议独立董事关于聘任高级管理人员发表的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on the appointment of senior management personnel, referencing compliance with company law and internal regulations. It does not contain financial data, audit results, or detailed management reports but is a formal statement related to board/management changes. The content aligns with announcements about changes in senior management rather than a full management report or audit. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management appointments, confirming this classification.
2021-06-02 Chinese
天士力因股份回购需通知债权人的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement by TianShiLi Pharmaceutical Group Co., Ltd. regarding a share repurchase plan approved by the board and shareholders. It notifies creditors about the share buyback and provides details on the repurchase price, quantity, funding source, and the rights of creditors to claim debts or request guarantees within 45 days. The document is relatively short (1490 characters) and serves as a formal notification to creditors about the share repurchase plan and related procedures. It does not contain financial statements or detailed financial analysis but is focused on the share repurchase activity and creditor notification. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers announcements of company share buybacks or sales of own shares.
2021-06-02 Chinese
天士力关于前十名股东持股情况的公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement from TianShiLi Pharmaceutical Group Co., Ltd. regarding the top 10 shareholders and their shareholding percentages as of the shareholder registration date. It includes detailed shareholding data and references a previous announcement about share repurchase. The document is titled as an "announcement" and contains no financial statements or management discussion. It is a notification about major shareholding information, specifically listing the top shareholders and their holdings. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding data, confirming it is not a full report or other type of filing.
2021-05-28 Chinese
天士力关于参加“天津辖区上市公司网上集体接待日”活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an online investor meeting event called '天津辖区上市公司网上集体接待日' scheduled for May 19, 2021. It provides details about the event's time, format (online), participants from the company, and how investors can join. There is no financial data, no report attached or referenced as being published, and no detailed financial or management discussion. The document is essentially a notice about an investor interaction event, not a report or transcript. It does not fit categories like Annual Report, Interim Report, Call Transcript, or Investor Presentation. It is an announcement related to investor relations but not a proxy, voting result, or regulatory filing per se. Given the options, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories. The document length is short (921 characters), and it is an announcement rather than a report or transcript.
2021-05-13 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.